ALPS Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-11,933
| Closed | -$300K | – | 954 |
|
|
2020
Q4 | $300K | Sell |
11,933
-363
| -3% | -$9.13K | ﹤0.01% | 714 |
|
|
2020
Q3 | $256K | Buy |
+12,296
| New | +$256K | ﹤0.01% | 741 |
|
|
2019
Q3 | – | Sell |
-10,004
| Closed | -$331K | – | 981 |
|
|
2019
Q2 | $331K | Sell |
10,004
-528
| -5% | -$17.5K | ﹤0.01% | 819 |
|
|
2019
Q1 | $369K | Buy |
10,532
+666
| +7% | +$23.3K | ﹤0.01% | 835 |
|
|
2018
Q4 | $328K | Sell |
9,866
-92,794
| -90% | -$3.08M | ﹤0.01% | 751 |
|
|
2018
Q3 | $5.17M | Buy |
102,660
+17,664
| +21% | +$889K | 0.03% | 160 |
|
|
2018
Q2 | $5.09M | Buy |
84,996
+5,167
| +6% | +$309K | 0.03% | 170 |
|
|
2018
Q1 | $3.66M | Buy |
79,829
+13,291
| +20% | +$609K | 0.03% | 169 |
|
|
2017
Q4 | $2.65M | Buy |
66,538
+5,263
| +9% | +$210K | 0.02% | 176 |
|
|
2017
Q3 | $2.45M | Sell |
61,275
-3,258
| -5% | -$130K | 0.02% | 175 |
|
|
2017
Q2 | $2.78M | Buy |
64,533
+3,950
| +7% | +$170K | 0.02% | 166 |
|
|
2017
Q1 | $1.9M | Sell |
60,583
-5,668
| -9% | -$177K | 0.01% | 182 |
|
|
2016
Q4 | $1.67M | Sell |
66,251
-15,859
| -19% | -$400K | 0.01% | 187 |
|
|
2016
Q3 | $2.03M | Buy |
82,110
+12,684
| +18% | +$314K | 0.02% | 182 |
|
|
2016
Q2 | $1.41M | Buy |
69,426
+14,407
| +26% | +$293K | 0.01% | 194 |
|
|
2016
Q1 | $839K | Sell |
55,019
-34,160
| -38% | -$521K | 0.01% | 193 |
|
|
2015
Q4 | $1.2M | Sell |
89,179
-11,381
| -11% | -$153K | 0.01% | 212 |
|
|
2015
Q3 | $14.1K | Buy |
100,560
+53,170
| +112% | +$7.46K | 0.01% | 191 |
|
|
2015
Q2 | $805K | Buy |
47,390
+26,119
| +123% | +$444K | 0.01% | 220 |
|
|
2015
Q1 | $257K | Buy |
+21,271
| New | +$257K | ﹤0.01% | 631 |
|